Protocol No
HCRN-GU15-215
Principal Investigator
Deepak Kilari
Phase
II
Summary
Most individuals who are not able to have the usual chemotherapy are given a different,
generally less effective type of chemotherapy called carboplatin. Recently, atezolizumab, which
is a type of immunotherapy, was approved by the FDA for the treatment of some patients in
your situation. Immunotherapy works by re-activating your immune system to fight cancer and
was shown to work in about 23% of patients with your cancer type, but who could not receive
the usual chemotherapy.
The purpose of this study is to evaluate any good and bad effects of treating urothelial of cancer
with atezolizumab plus bevacizumab. Atezolizumab is already a U.S. Food and Drug
Administration (FDA) approved standard treatment for advanced urothelial cancer for some
people who cannot safely receive cisplatin chemotherapy, and this study will assess the effect
(good or bad) of adding bevacizumab to standard atezolizumab. You will receive atezolizumab
plus bevacizumab as the first treatment for your advanced urothelial cancer. Bevacizumab plus
atezolizumab has shown safety when combined. The study doctors would like to determine if
the combination of atezolizumab and bevacizumab is more effective in controlling your cancer.
Description
The purpose of this study is to evaluate any good and bad effects of treating urothelial of cancer
with atezolizumab plus bevacizumab.
with atezolizumab plus bevacizumab.
Participating Institutions
Froedtert Hospital
Status
OPEN TO ACCRUAL
ClinicalTrials.gov